Dianthus Therapeutics (NASDAQ:DNTH) Price Target Raised to $56.00

Dianthus Therapeutics (NASDAQ:DNTH) had its target price hoisted by research analysts at Raymond James from $51.00 to $56.00 in a report issued on Friday,Benzinga reports. The firm presently has an “outperform” rating on the stock. Raymond James’ price objective indicates a potential upside of 93.97% from the stock’s previous close.

Several other analysts also recently weighed in on DNTH. HC Wainwright restated a “buy” rating and issued a $40.00 price objective on shares of Dianthus Therapeutics in a report on Thursday, September 26th. Oppenheimer began coverage on shares of Dianthus Therapeutics in a report on Thursday, October 3rd. They set an “outperform” rating and a $48.00 price objective on the stock. Wedbush dropped their target price on shares of Dianthus Therapeutics from $38.00 to $36.00 and set an “outperform” rating on the stock in a research report on Friday, August 9th. Baird R W raised shares of Dianthus Therapeutics to a “strong-buy” rating in a report on Friday, July 26th. Finally, Robert W. Baird started coverage on Dianthus Therapeutics in a research note on Friday, July 26th. They issued an “outperform” rating and a $58.00 target price for the company. Eight analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Buy” and an average price target of $45.86.

Dianthus Therapeutics Trading Down 3.4 %

NASDAQ:DNTH traded down $1.03 during midday trading on Friday, hitting $28.87. 67,241 shares of the company traded hands, compared to its average volume of 192,907. The firm’s fifty day moving average is $27.75 and its 200-day moving average is $26.45. The firm has a market capitalization of $847.91 million, a P/E ratio of -5.21 and a beta of 1.84. Dianthus Therapeutics has a 12-month low of $6.58 and a 12-month high of $33.77.

Dianthus Therapeutics (NASDAQ:DNTH) last released its earnings results on Thursday, November 7th. The company reported ($0.74) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.59) by ($0.15). The business had revenue of $2.17 million during the quarter, compared to analysts’ expectations of $1.07 million. Dianthus Therapeutics had a negative return on equity of 21.03% and a negative net margin of 1,376.42%. On average, research analysts expect that Dianthus Therapeutics will post -2.28 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of DNTH. Quest Partners LLC grew its holdings in Dianthus Therapeutics by 112,400.0% during the third quarter. Quest Partners LLC now owns 1,125 shares of the company’s stock worth $31,000 after acquiring an additional 1,124 shares during the period. SG Americas Securities LLC acquired a new stake in shares of Dianthus Therapeutics during the second quarter valued at $112,000. The Manufacturers Life Insurance Company purchased a new position in shares of Dianthus Therapeutics during the second quarter valued at approximately $236,000. WINTON GROUP Ltd purchased a new stake in shares of Dianthus Therapeutics in the second quarter valued at $265,000. Finally, Point72 DIFC Ltd purchased a new stake in Dianthus Therapeutics in the second quarter valued at approximately $334,000. 47.53% of the stock is owned by hedge funds and other institutional investors.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.